Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
goserelin + letrozole + ribociclib
- Development stage
- Phase 3
- Lead developer
- Novartis
- Modality
- Small Molecules, Peptides
- Administration
- Oral, Subcutaneous
01
Overview
A combination therapy consisting of goserelin (an LHRH agonist), letrozole (an aromatase inhibitor), and ribociclib (a CDK4/6 inhibitor). This regimen is used for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer, particularly in pre/perimenopausal women and male patients. The combination works by suppressing hormone production (goserelin), blocking estrogen synthesis (letrozole), and inhibiting cell cycle progression (ribociclib) to prevent cancer cell growth and proliferation.
02
Targets
CYP19A1 (Aromatase)CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on goserelin + letrozole + ribociclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on goserelin + letrozole + ribociclib.